Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27677864 | 0.78 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL745921 | 0.76 | HTR2C (0.65) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL30075655 | 0.76 | HTR2C (0.69) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL15935172 | 0.76 | HTR2C (0.69) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL27821350 | 0.76 | HTR2C (0.46) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL27840659 | 0.75 | SLC6A2 (0.56) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL27811328 | 0.74 | HTR6 (0.38) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL1789472 | 0.74 | PTGDR2 (0.44) | HTR2CSLC6A2SLC6A4HTR1A | |
| SCHEMBL1789474 | 0.73 | PTGDR2 (0.47) | HTR2CSLC6A2SLC6A4HTR1A | |
| Tert-Butyl Formate SCHEMBL27794226 | 0.73 | HTR2C (0.52) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102439008-B | 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | ORTHO MCNEIL JANSSEN PHARM | 2015-04-29 | — | — | CN | disclosed |
| CN-103342695-B | 1',3'-disubstituted-4-pheny-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-ones | ORTHO MCNEIL JANSSEN PHARM | 2015-04-22 | — | — | CN | disclosed |
| CN-101801951-B | 1 ', 3 ' -disubstituted-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -ones | ORTHO MCNEIL JANSSEN PHARM | 2013-11-13 | — | — | CN | disclosed |
| CN-103342695-A | 1',3'-disubstituted-4-pheny-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-ones | ORTHO MCNEIL JANSSEN PHARM | 2013-10-09 | — | — | CN | disclosed |
| CN-101861316-B | Imidazo [1,2-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2013-08-21 | — | — | CN | disclosed |
| CN-102439008-A | 1,2, 3-triazolo [4,3-a ] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | disclosed |
| CN-101861316-A | Imidazo [1,2-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2010-10-13 | — | — | CN | disclosed |
| CN-101801951-A | 1 ', 3 ' -disubstituted-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -ones | ORTHO MCNEIL JANSSEN PHARM | 2010-08-11 | — | — | CN | disclosed |